MedTrace Logo

The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia

NCT04594733 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

Evaluation of the effect of combinatorial treatment of fibromyalgia patients (standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care on subjective pain measurement Revised Fibromyalgia Impact Questionnaire (FIQR).

Conditions

  • Fibromyalgia

Interventions

DRUG

minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo

minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo

DRUG

Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)

Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Michael G Hillegass, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2022-08-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594733 on ClinicalTrials.gov